Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
A novel non-antibiotic approach for treating C. difficile infection
EF 2023-24
Résumé
Clostridioides difficile (C. difficile) is an infectious bacterium that colonizes the colon and causes severe diarrhea, which can lead to life-threatening complications like sepsis and toxic megacolon. C. difficile infection (CDI) is particularly prevalent in individuals taking antibiotics. This is because antibiotics affect both harmful and healthy bacteria, depleting the endogenous gut microbiome which normally protects against CDI. Paradoxically, antibiotics are also the current treatment for CDI, resulting in high rates of reinfection. We have taken a non-antibiotic approach to treating CDI; we have created a drug that does not kill C. difficile directly, but instead disrupts its ability to harm the host. Specifically, our drug targets a toxin produced by C. difficile, which when absorbed by the host, causes the symptoms of infection. Our small molecule engages with and neutralizes the toxin in the colon before its absorption by the host, thus preventing the onset of the disease. The chemical structure of our drug is derived from a molecule that naturally interacts with the toxin within the cell. Subtle modifications to its structure ensure its efficacy in the colonic environment. Preliminary data suggests our drug remains active in the presence of dietary minerals found in the colon, like calcium. We now aim to determine the efficacy of our drugs in a mouse model of CDI to compare our proposed therapeutic strategy directly against the antibiotics currently used to treat CDI in humans. Further, we plan on examining the bacterial composition of the microbiome throughout the course of infection and treatment to determine whether our approach supports the re-establishment of a diverse and healthy microbiome, and as a consequence, better protection against reinfection.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506162
Name
Keogh Liam J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A novel non-antibiotic approach for treating C. difficile infection
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoprocessing; C. Difficile; C. Difficile Infection; Germination; Microbiome; Murine Model; Phytic Acid; Spore; Toxin
Abstract
Clostridioides difficile (C. difficile) is an infectious bacterium that colonizes the colon and causes severe diarrhea, which can lead to life-threatening complications like sepsis and toxic megacolon. C. difficile infection (CDI) is particularly prevalent in individuals taking antibiotics. This is because antibiotics affect both harmful and healthy bacteria, depleting the endogenous gut microbiome which normally protects against CDI. Paradoxically, antibiotics are also the current treatment for CDI, resulting in high rates of reinfection. We have taken a non-antibiotic approach to treating CDI; we have created a drug that does not kill C. difficile directly, but instead disrupts its ability to harm the host. Specifically, our drug targets a toxin produced by C. difficile, which when absorbed by the host, causes the symptoms of infection. Our small molecule engages with and neutralizes the toxin in the colon before its absorption by the host, thus preventing the onset of the disease. The chemical structure of our drug is derived from a molecule that naturally interacts with the toxin within the cell. Subtle modifications to its structure ensure its efficacy in the colonic environment. Preliminary data suggests our drug remains active in the presence of dietary minerals found in the colon, like calcium. We now aim to determine the efficacy of our drugs in a mouse model of CDI to compare our proposed therapeutic strategy directly against the antibiotics currently used to treat CDI in humans. Further, we plan on examining the bacterial composition of the microbiome throughout the course of infection and treatment to determine whether our approach supports the re-establishment of a diverse and healthy microbiome, and as a consequence, better protection against reinfection.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Keogh, Liam J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~